HIV mutation literature information.


  Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.
 PMID: 34064774       2021       Viruses
Result: Seven SDRMS increased in prevalence among NNRTI-experienced persons including K101E, Y181V, Y188C, G190S, P225H, and M230L while four decreased in prevalence including L100I, V106A, K101P, and V181I.


  HIV-1 molecular transmission network among sexually transmitted populations in Liaoning Province, China.
 PMID: 34260561       2021       Medicine
Result: Among them, 9 cases were protease inhibitor-related resistance, and the main resistance sites were L33F, V82A, Q58E, M46L, M46I; There were 4 cases of nucleoside reverse transcriptase inhibitor resistance, the main mutation sites were V75VI, K219Q, T215A, K65R; There were 5 cases of non-nucleoside reverse transcriptase inhibitor resistance,
Discussion: Mutations K65R, Y181C+G190S, which produced high drug resistance, did not enter the transmission network.


  HIV-1 Drug Resistance and Genetic Transmission Networks Among MSM Failing Antiretroviral Therapy in South China 2014-2019.
 PMID: 34377002       2021       Infection and drug resistance
Table: G190A/S
Discussion: V106I/M, K103N/Q, G190A/S, and Y181C were the major NNRTI-associated mutations, similar to those in other cities in China and other countries, and showed broad-spectrum resistance possibly caused by the wide use of NNRTIs.


  Correlation of HIV-1 drug resistant mutations and virologic failure.
 PMID: 34584606       2021       The Pan African medical journal
Introduction: These mutations included M184V, K65R,D67N,K70R,K219Q,Q151M, T215F, M41L, T69N, V75M, M41L, T69N, V75M, D67G, V75M, M184I, T215N, M41LM, T215N, K219N,210W, T215Y as NRT
Table: G190S


  Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study.
 PMID: 34622871       2021       Medicine
Result: K103N/S 56 (21.0%), G190S/A 39 (14.6%), Y181C/I 29 (10.9%), V108I 13 (4.9%), P225H 12 (4.5%), Y188L 7 (2.6%), M230L 7 (2.6%), L100I 5 (1.9%), V106 M 5 (1.9%), and K101P 2 (0.7%) were the mutations conferring resistance to NNRTIs.


  Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort.
 PMID: 32205723       2020       AIDS (London, England)
Discussion: Further reduction of the overall IND rate could be achieved by including probes for alternative variants at the codons tested, such as M184I and G190S, depending on the frequency of these mutations in the target population.


  Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.
 PMID: 32180823       2020       Drugs in context
Introduction: Other single substitutions including G190E/S, V106A, Y188L, and M230L reduced DOR susceptibility >10-fold.
Introduction: The G190S, Y188L, and M230L substitutions confer >95-fold resistance.


  HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naive HIV-infected individuals.
 PMID: 32119691       2020       PloS one
Table: G190A/S


  Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.
 PMID: 32102660       2020       BMC infectious diseases
Result: L228R was correlated with known DRMs G190S (cKa/KsL228R-G190S = 2.25, LOD = infinity) and K65R (cKa/KsK65R
Result: Among them, the known DRMs Y181C and G190S showed the strongest correlation (cKa/KsY181C-G190S = 22.86, LOD = infinity).
Result: In this study, 40 out of 2034 (1.97%) treatment-naive CRF01_AE-infected patients had transmitted DRMs, with the common DRMs comprising K103 N, G190S, K101E, T215S, K65R, and K219Q.


  Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001-2017).
 PMID: 31922125       2020       EClinicalMedicine
Abstract: One NRTI-associated (M184V/I) and three NNRTI-associated (K103N/S, Y181C/I and G190A/S) mutations had high percentages in ART-naive and ART-treated individuals, and these mutations conferred high-level resistance to 3TC, EFV and/or NVP.
Discussion: K103N, Y181C/I and G190S/A) conferred high percentages (88-90%) of high- and intermediate-level resistance to EFV and NVP in ART-treated individuals across the country.
Discussion: The finding that a few NRTI-associated (M184V/I) and NNRTI-associated (



Browser Board

 Co-occurred Entities




   Filtrator